Draft EU Guidance on Medication Errors
|
|
- Patrick Gardner
- 6 years ago
- Views:
Transcription
1 Draft EU Guidance on Medication Errors Revision after PSQCWG and PRAC consultation PSQCWG meeting Brussels, 11 February 2015 Presented by Dr. Thomas Goedecke Senior Scientific Officer, Regulatory Affairs and Best Evidence Department An agency of the European Union
2 Outline Feed-back on consultation: Guide I: Good practise guide on recording, coding, reporting and assessment of medication errors, developed by PMG 1 (Lead: Thomas Goedecke, EMA); Guide II: Good practise guide risk minimisation and prevention of medication errors, developed by PMG 2 (Lead: Kathryn Ord, UK); Addendum of Guide II: Risk minimisation strategies for high strength/fixed dose combination insulins, developed by PRAC drafting group (Co-Leads: Menno van der Elst, NL and Thomas Goedecke, EMA); Purpose of this presentation: Detailed feed-back on PSQCWG members comments Feed-back on PRAC position Agreement on the next steps 1
3 Comments received PSQCWG (18 Dec Jan 15) Guide I: Ministry of Health Italy, Comité Permanent des Médecins Européens (CPME), National School of Public Health Romania, Agency for Quality and Accreditation in Health Care and Social Welfare Croatia; Drug Commission of the German Medical Association (AkdÄ); Pharmacovigilance Risk Assessment Committee (PRAC) (9 Dec Jan 15) Guide I: IE, NL, ES, HR, SE, UK; Guide II: DE, SE, UK; Addendum: SE, DE; Patient/HCP expert consultation Addendum: H. Lebanova (PGEU), W. Wientjens (IDF-Europe), J.M. Otero (ISMP-España), C. Kirke (Tallaght Hospital Ireland), M. Lundberg (FEND), J. Wilkinson (PGEU); 2
4 Guide I Key issues addressed from previous round Conceptual definition for medication errors: Medication error is a failure in the drug treatment process that leads to, or has the potential to lead to, harm to the patient. Endorsed by national Competent Authorities (NCAs) of IE, NL, ES, HR, SE, UK; DE, AkdÄ and CPME support broader definition including acts of omission/commission; Endorsed by PRAC Plenary Feb 15; Collaboration NCA-PSO: NL proposal that national Patient Safety Organisation (PSO) informs NCA of medication errors associated with adverse drug reaction(s) (ADR) as single reports brought to PSO s attention to allow further processing in EudraVigilance; 3
5 Guide I PSQCWG comments Definition ME (4.3): Definition too narrow, at pharmacy distribution faulty IT systems also cause errors. A distinction to devices (pumps, robots, etc.) should be made. Omissions are the most serious medication errors (for example omission of anti-coagulants), therefore the last part of the definition should not be deleted. Acts of omissions/commissions were included in previous definition, however MS felt this would cause problems at national level with regard to reporting obligations and potential liability issues, therefore PRAC agreed on a narrow definition. The provided examples for errors of omission (e.g. failure to monitor blood glucose levels when switching patients from a standard to a high dose insulin product) and errors of commission (e.g. wrong dose administered) are considered prescribing errors. These examples have been deleted. 4
6 Guide I PSQCWG comments continued Definition Adverse Event (4.1): Adverse event is often referred to as "medication related adverse event" - to make a difference to other kind of adverse events (falls, infections, wrong side surgery). We suggest the document should made the distinction between «adverse events» and «medication related adverse events». Text amended accordingly. Definition Adverse Drug Reaction (4.2): I wouldn t say that it's an adverse effect if, as in offlabel use, the possible negative effects are taken into account from the very beginning.. This definition of ADR is provided in DIR and GVP VI.A.2.1, so can not be changed. Root cause analysis (4.4): Different methods are used in analysis of errors and root cause analysis is not always the most appropriate method. Suggestion to change to systems analysis. Text amended accordingly. Further discussion needed on the term system analysis ; 5
7 Guide I PSQCWG comments continued Parameters to follow-up (table 2): List too long and clinical staff nor hospital administrative staff will have time. List is a recommendation for ICSR senders (MAH, NCA) for case followup as appropriate, and not a requirement for HCPs as initial reporter. Collaboration NCA PSO (6.2): The Italian Ministry of Health proposes to add: Where a national system for reporting patient safety incidents exists a formal agreement have to be signed by the two bodies, NCA and PSO, in order to allow the exchange of information. A statement has been added. Role of patients/hcp (6.3): Intentional formulation" is clearly unsufficient to guarantee reporting cf. the CIRS experience (Critical Incident Reporting System) in the many fields where it is used.? Further clarification required 6
8 Guide I PRAC position on errors at monitoring stage ME are unintended mistakes in the processes of prescribing, dispensing, preparation, administering or monitoring (drug treatment process); Some NCAs consider that monitoring errors are out of scope of this regulatory guidance; PRAC decision to delete monitoring from guide I at Plenary Feb 15; Introduction: Medication errors generally refer to unintended mistakes in the processes of prescribing, dispensing, administering or monitoring of medicinal products in clinical practice. Scope: The primarily scope is to support the recording, reporting and assessment of suspected adverse reactions (serious and non-serious) associated with an error in the prescribing, dispensing, preparation, administration or monitoring of a medicinal product... Def. potential ME: The term potential medication error refers to... This includes all possible mistakes in the prescribing, dispensing, administration, preparation or monitoring of a medicinal product by all persons who are involved in the medication process. Special situations: Coding at different stages of medication error - Medication errors can be a series of events as shown in figure 2 at prescribing, dispensing, preparation, administration or monitoring stage. 7
9 Guide II Input on examples for root cause analysis Chapter describes the basic steps of root cause analysis: Identification of the problem (including details of what happened, when, where and in what situation, and what the impact of the event is on stakeholders) Identification of causes of the problem (describe the processes that led to the problem and identify the stages at which error could have or did occur) Identification of solutions (identify possible or potential solutions from sources of error in the process) Could PSQCWG members provide practical examples where conduct of RCA has resulted in effective risk minimisation and prevention of medication errors with authorised medicines? 8
10 Next steps PSQCWG orientation Is PSQCWG content with the proposed next steps: Feb 15: EU regulatory network written consultation (PRAC, CHMP, CMDh, COMP) 18 Feb 15: Consultation and approval by the Implementation Group (IG) of Member States and EMA pharmacovigilance governance structure 17 Mar 15: ERMS approval of final draft for public consultation Apr-May 15: Public consultation Sep 15: Final guidance for publication 9
11 Thank you for your attention Further information European Medicines Agency 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone +44 (0) Facsimile +44 (0) Send a question via our website Follow us
EV Reporting process for users: Creating and sending ICSRs using EVWEB part II
EV Reporting process for users: Creating and sending ICSRs using EVWEB part II Training Module EV-M3e An agency of the European Union Content Summary Introduction Nullifications and Amendments Creating
More informationMedDRA User Group. Paris, April 16, 2015 Victoria Newbould, European Medicines Agency. An agency of the European Union
MedDRA User Group Paris, April 16, 2015 Victoria Newbould, European Medicines Agency An agency of the European Union HMA meeting 28 November 2013 HMA agreed with the deliverables to be completed over the
More informationAdopted by Pharmacovigilance Risk Assessment Committee 20 February Adopted by Pharmacovigilance Inspectors Working Group 21 March 2014
21 March 2014 EMA/INS/PhV/192231/2014 Union procedure on the management of pharmacovigilance inspection findings which may impact the robustness of the benefit-risk profile of the concerned medicinal Adopted
More informationPatient Registries Initiative Background, Achievements, Next steps
Patient Registries Initiative Background, Achievements, Next steps 21 November 2017 ENCePP Plenary meeting Presented by Xavier Kurz, Surveillance & Epidemiology Service, European Medicines Agency An agency
More informationSafeguarding public health. The New PV Legislation. Perspective from a Member State
Safeguarding public health The New PV Legislation Perspective from a Member State Mick Foy Reinforcing patient safety in Europe, Zagreb June 2011 Content Background The new EU PV Package ADR Definition
More informationGood Pharmacovigilance Practice. Overview of GVP Modules on ADR, PSURs, Signal Management and Additional Monitoring Mick Foy - MHRA
Good Pharmacovigilance Practice Overview of GVP Modules on ADR, PSURs, Signal Management and Additional Monitoring Mick Foy - MHRA Content ADR Reporting Definition & Increased scope Transition arrangements
More informationDelivery time frame for the EU portal and EU database
17 December 2015 EMA/760345/2015 Endorsed Draft time frame presented to European Medicines Agency Management Board 01 October 2015 Draft timeframe presented to IT Directors and Member States during the
More informationUse of disease registries for benefitrisk evaluation of medicines: A regulatory perspective. DIA Europe April Basel, Switzerland
Use of disease registries for benefitrisk evaluation of medicines: A regulatory perspective DIA Europe 2018-17-19 April Basel, Switzerland Presented by Xavier Kurz Head of Service Surveillance and Epidemiology
More informationImplementation of the new pharmacovigilance legislation: Overall update and activities in 2013
Implementation of the new pharmacovigilance legislation: Overall update and activities in 2013 Workshop for micro, small and medium-sized enterprises (SMEs) European Medicines Agency (EMA), London 26 April
More informationGuideline on good pharmacovigilance practices (GVP)
9 October 2017 2017 EMA/118465/2012 Rev 1* Guideline on good pharmacovigilance practices (GVP) Module XV Safety communication (Rev 1) Date for coming into effect of first version 24 January 2013 Draft
More informationGuideline on good pharmacovigilance practices (GVP)
1 2 26 July 2012 EMA/118465/2012 3 4 Guideline on good pharmacovigilance practices (GVP) Module XV Safety communication 5 Draft finalised by the Agency in collaboration with Member States and submitted
More informationWork plan for GCP Inspectors Working Group for 2018
22 March 2018 EMA/87812 /2018 Committees and Inspections Chairperson: Ana Rodriguez The activities outlined in the work plan for 2018 have been agreed in view of preparation for the Agency s relocation
More informationOverview of comments received on draft 'Good practice guide on recording, coding, reporting and assessment of medication errors' (EMA/762563/2014)
23 October 2015 EMA/190895/2015 Pharmacovigilance Risk Assessment Committee Overview of comments received on draft 'Good practice guide on recording, coding, reporting and assessment of medication errors'
More informationThe New EU PV Legislation: View from the European Commission
The New EU PV Legislation: View from the European Commission International seminar 26 May 2011 Lenita LINDSTRÖM Senior Policy Officer Pharmaceuticals Unit/DG SANCO Rationale for the revision Calls for
More informationGuideline for the notification of serious breaches of Regulation (EU) No 536/2014 or the clinical trial protocol
1 2 31 January 2017 EMA/430909/2016 3 4 5 Guideline for the notification of serious breaches of Regulation (EU) No 536/2014 or Draft Adopted by GCP Inspectors Working Group (GCP IWG) 30 January 2017 Adopted
More informationCorporate Induction: Part 2
Corporate Induction: Part 2 Identification of preventable Adverse Drug Reactions from a regulatory perspective March 1 st 2013, EMA Workshop on Medication Errors Presented by Almath Spooner, Pharmacovigilance
More informationThe Pharmaceutical Risk Assessment Committee (PRAC) of the EMA
The Pharmaceutical Risk Assessment Committee (PRAC) of the EMA Albert van der Zeijden (PRAC member) Expert representing patients perspective Eurordis Summerschool Friday June 5, 2015 Content The history
More informationLessons from the EMA Patient Registries Initiative
Lessons from the EMA Patient Registries Initiative STAMP Commission Expert Group 8 th June 2018 Presented by Peter Arlett, with contributions from Patricia McGettigan and Jane Moseley Head of Pharmacovigilance
More informationSafeguarding public health. The New PV Legislation its Impact on PV & MI
Safeguarding public health The New PV Legislation its Impact on PV & MI Sarah Vaughan - MHRA PIPA 2013 Manager s Meeting 13 th February 2013 Content Scope of change Key areas - ADR reporting - DDPS to
More informationINVOLVING PATIENTS IN PHARMACOVIGILANCE EPF TOOLKIT. Susanna Palkonen, EPF Board Member
INVOLVING PATIENTS IN PHARMACOVIGILANCE EPF TOOLKIT Susanna Palkonen, EPF Board Member EPF About us Independent, non-governmental umbrella organisation set up in 2003 VISION: High-quality, patientcentred,
More informationPatient Registry Initiative- Strategy and Mandate of the Cross-Committee Task Force
5 May 2017 EMA/180341/2017 Inspections, Human Medicines, Pharmacovigilance and Committees Division Patient Registry Initiative- Strategy and Mandate of the Cross-Committee Task Force EMA Initiative 1.
More informationEMA Patients and Consumers Annual Training Overview:
EMA Patients and Consumers Annual Training Overview: 2007-2016 Presented by Maria Mavris on 20 September 2017 Public Engagement Department, Stakeholders and Communication Division An agency of the European
More informationA Dedicated Post Authorisation Measure Submission Form
A Dedicated Post Authorisation Measure Submission Form An improved way of submitting your PAM to the EMA Presented by Hector Boix Perales on 03 July 2017 Procedure Management Department Human Medicines
More informationRemediation, Resolution and Outcomes
IPA Pharmaceutical Forum 2018 22-23 February 2018 Presented by Andrei Spinei Manufacturing and Quality Compliance, European Medicines Agency An agency of the European Union Contents 1.EMA EU Network 2.Remediation
More informationSCOPE Work Package 4 ADR Collection. Medication Errors
Medication Errors Contents Acknowledgments 3 1. Introduction 4 1.3 Definitions and abbreviations 5 2. Medication errors 7 2.1 Coding of medication errors 7 2.2 Exemption from liability for HCPs when reporting
More informationPharmacovigilance assessor. National Institute of Pharmacy and Nutrition (OGYÉI) (Hungary) Senior hospital Pharmacist
Curriculum vitae PERSONAL INFORMATION Gyorgyi Fodor WORK EXPERIENCE September 2011 Present Pharmacovigilance assessor National Institute of Pharmacy and Nutrition (OGYÉI) (Hungary) Benefit/risk assessment,
More informationGuidance for the conduct of good clinical practice inspections
23 August 2017 EMA/839541/2015 Guidance for the conduct of good clinical practice inspections Adopted by GCP Inspectors Working Group (GCP IWG) 4 September 2017 Keywords Conduct of GCP inspections 30 Churchill
More informationQuestions and answers on the procedure of PIP compliance verification at EMA, and on paediatric rewards
15 December 2014 EMA/PDCO/179892/2011 Rev. 2 Product Development Scientific Support Paediatric Medicines Questions and answers on the procedure of PIP compliance verification at EMA, and on paediatric
More informationStrengthening Collaborations for Operating Pharmacovigilance in Europe (SCOPE) Joint Action
www.scopejointaction.eu Strengthening Collaborations for Operating Pharmacovigilance in Europe (SCOPE) Joint Action The SCOPE Joint Action has received funding from the European Union Contents 1. Overall
More informationStandard operating procedure
Standard operating procedure Title: Referral procedures in accordance with the provisions of Articles 33(4), 34 and 35 of Directive 2001/82/EC, and Article 13 of Commission Regulation (EC) No 1234/2008,
More informationContinuous Professional Development of Health Professionals European Context
Continuous Professional Development of Health Professionals European Context Balázs Lengyel European Commission Health and Food Safety Directorate-General 20 June 2017 Citizens opinion: "Well trained medical
More informationReconciliation of Medicines on Admission to Hospital
Reconciliation of Medicines on Admission to Hospital Policy Title State previous title where relevant. State if Policy New or Revised Policy Strand Org, HR, Clinical, H&S, Infection Control, Finance For
More informationReflection Paper on Medicinal Product Supply Shortages Caused by Manufacturing/GMP Compliance Problems. Outcome of 10 September 2012 Workshop
Reflection Paper on Medicinal Product Supply Shortages Caused by Manufacturing/GMP Compliance Problems Outcome of 10 September 2012 Workshop Management Board Meeting - Agenda Point B10 04 October 2012
More informationEuropean Patients Academy (EUPATI) Update
European Patients Academy (EUPATI) Update EMA meeting with patient/consumer organisations 11 Dec 2013 Maria Mavris EURORDIS // EUPATI WP4 Co-Lead For patient-centric medicines R&D and to contribute to
More informationElectronic submission of information on medicinal products in accordance to Article 57(2) requirements: Maintenance submission
Electronic submission of information on medicinal products in accordance to Article 57(2) requirements: Maintenance submission SME workshop: Focus on quality for medicines containing chemical entities
More information4. Multi Stakeholder: Late & Early Dialogue
4. Multi Stakeholder: Late & Early Dialogue Presented by Spiros Vamvakas on 19 September 2017 Head of Scientific Advice Office An agency of the European Union Background Starting point: Regulators and
More informationAssessment of patient, consumer and healthcare professional organisations compliance with EMA eligibility criteria
15 March 2018 EMA/698917/2017 Stakeholders and Communication Division Assessment of patient, consumer and healthcare professional organisations compliance with EMA eligibility criteria 1. Introduction
More informationEMEA/CHMP WORKING GROUP WITH HEALTHCARE PROFESSIONALS ORGANISATIONS (HCP WG) FINAL RECOMMENDATIONS AND PROPOSALS FOR ACTION
European Medicines Agency London, 6 th of February 2009 Doc. Ref.: EMEA/185036/2008 EMEA/CHMP WORKING GROUP WITH HEALTHCARE PROFESSIONALS ORGANISATIONS (HCP WG) FINAL RECOMMENDATIONS AND PROPOSALS FOR
More informationMeasures of impact of pharmacovigilance processes (3.3)
Measures of impact of pharmacovigilance processes (3.3) Session 4 - Reports from breakout sessions: gaps and observations Workshop: Measuring the Impact of Pharmacovigilance Activities London, 5-6 December
More informationClinical data Publication Webinar
Clinical data Publication Webinar Presented by Documents Access & Publication Service 23 March 2017 An agency of the European Union Clinical Data Publication (CDP) Guidance Introduction, scope, definitions
More informationMinutes of EMA Human Scientific Committees Working Party with Patients and Consumers Organisations (PCWP) meeting with all eligible organisations
31 January 2014 EMA/792279/2013 Patients and Healthcare Professionals Department Minutes of EMA Human Scientific Committees Working Party with Patients and Consumers Organisations (PCWP) meeting with all
More informationBETTER REGULATION OF MEDICINES INITIATIVE (BROMI): FIFTH REPORT ON PROGRESS
A2 BETTER REGULATION OF MEDICINES INITIATIVE (BROMI): FIFTH REPORT ON PROGRESS March 2012 A3 BETTER REGULATION OF MEDICINES INITIATIVE (BROMI) FIFTH REPORT ON PROGRESS Chief Executive s foreword In January
More information1. Have you or a member of your family had first-hand experience of an adverse event or experienced harm in a healthcare setting in your country?
Patient Safety p.1 Submission: 163 Stakeholder group Other other, please specify Hospital Country Germany Role in organisation management Number of employees 250 - Your organisation's geographical area
More informationEnsuring our safeguarding arrangements act to help and protect adults PRACTICE GUIDANCE FOR REPORTING MEDICATION INCIDENTS INTO SAFEGUARDING
Ensuring our safeguarding arrangements act to help and protect adults PRACTICE GUIDANCE FOR REPORTING MEDICATION INCIDENTS INTO SAFEGUARDING Contents Page 1.0 Purpose 2 2.0 Definition of medication error
More informationCompassionate Use Systems in the EU How to improve for early access to patients
Compassionate Use Systems in the EU How to improve for early access to patients Author: EFPIA* Date: 10/03/2016 * Version: Final Sabine Atzor, Valdelene Iglesias Langer, EFPIA Agenda 1. Early Access Schemes
More informationGuidance notes for patient safety and pharmacovigilance in patient support programmes
Guidance notes for patient safety and pharmacovigilance in patient support programmes Authors: The ABPI Pharmacovigilance Expert Network Version: 2.14 Date: March 2018 Acknowledgements: We thank the many
More information1. PURPOSE 2. SCOPE 3. RESPONSIBILITIES
1. PURPOSE The purpose of this standard operating procedure (SOP) is to inform all Alexion personnel, and applicable service providers who become aware of a Pharmacovigilance (PV) Event of their responsibility
More information<Insert Picture Here> Some Background and What You Should Know and Do Now to Prepare
1 E2B (R3): Some Background and What You Should Know and Do Now to Prepare The following is intended to outline our general product direction. It is intended for information purposes
More informationAnnual report of the Good Clinical Practice Inspectors Working Group 2016
15 June 2017 EMA/INS/GCP/763873/2016 Committees and Inspections Annual report of the Good Clinical Practice Inspectors Working Group 2016 Adopted by the GCP IWG on 2 June 2017 30 Churchill Place Canary
More informationGuidance for applicants requesting scientific advice
7 December 2017 EMEA/CVMP/SAWP/172329/2004 Rev. 5 Veterinary Medicines Division Introduction The Scientific Advice Working Party (SAWP-V) of the Committee for Medicinal Products for Veterinary Use (CVMP)
More informationStudy definition of CPD
1. ABSTRACT There is widespread recognition of the importance of continuous professional development (CPD) and life-long learning (LLL) of health professionals. CPD and LLL help to ensure that professional
More informationStandard operating procedure
Standard operating procedure Title: Evaluation procedure for applications and requests for the establishment or review of Maximum Residue Limits (MRLs) Status: PUBLIC Document no.: SOP/V/4150 Lead author
More informationThe European network evaluation of the PHAR QA framework of competences for...
The European network evaluation of the PHAR QA framework of competences for... The PHAR QA ( Quality assurance in European pharmacy education and training ) funded by the European Commission, will produce
More informationA new Youth Guarantee for Europe: Roadmap for Member States
A new Youth Guarantee for Europe: Roadmap for Member States Max UEBE Head of Unit C.2 Sectorial employment challenges, Youth Employment and Entrepreneurship DG Employment, Social Affairs and Inclusion
More informationList of nationally authorised medicinal products
26 October 2017 EMA/691325/2017 Human Medicines Evaluation Division Active substance: Technetium (99mTc) pertechnetate Procedure no.: PSUSA/00002866/201703 30 Churchill Place Canary Wharf London E14 5EU
More informationTherefore the provision of medicines is an area for which a Community regulatory framework should be properly supervised to ensure full and
European Association of Pharmaceutical Full-line Wholesalers (GIRP) response to the European Commission Consultation regarding Community action on Health Services Introduction Firstly, GIRP welcomes the
More informationPatient Centricity In Pharmacovigilance:
Patient Centricity In Pharmacovigilance: New Directions, New Horizons Background The importance of Pharmacovigilance (PV) as a science and its role in effective patient care in clinical practice and public
More informationThis policy applies to all staff and contractors working for the Agency and all persons working within its demised premises.
6 September 2012 EMA/65832/2011 Executive Director POLICY/0004 Status: Public Effective date: 06-Sep-12 Review date: 06-Sep-13 Supersedes: POLICY/0004 (18-APR-11) 1. Introduction and purpose It is the
More informationTransmission to CHMP December Adoption by CHMP for release for consultation December 2008
September 2010 EMA/CHMP/ICH/645469/2008 ICH guideline Q4B annex 7 (R2) to note for evaluation and recommendation of pharmacopoeial texts for use in the ICH regions on dissolution test general chapter Step
More informationJoint Statement on the Application of Good Clinical Practice to Training for Researchers
Joint Statement on the Application of Good Clinical Practice to Training for Researchers HRA, MHRA, Devolved Administrations for Northern Ireland, Scotland and Wales v1.1 12/10/17 Summary This joint statement
More informationSTANDARD OPERATING PROCEDURE
STANDARD OPERATING PROCEDURE Title Reference Number Risk Assessment SOP-RES-002 Version Number 2 Issue Date 29 th Sep 2016 Effective Date 10 th Nov 2016 Review Date 10 th Nov 2018 Author(s) Reviewer(s)
More informationFOOD AND DRUGS AUTHORITY GUIDELINES FOR QUALIFIED PERSON FOR PHARMACOVIGILANCE
FOOD AND DRUGS AUTHORITY GUIDELINES FOR QUALIFIED PERSON FOR PHARMACOVIGILANCE Document No. : FDA/SMC/SMD/GL-QPP/2013/03 Date of First Adoption : 1st February, 2013 Date of Issue : 1 st March, 2013 Version
More information...FREEDOM TO EXPLORE YOUR REGULATORY NEEDS
...FREEDOM TO EXPLORE YOUR REGULATORY NEEDS 1 Table of Contents Pg 3 Pg 4 Pg 5 About Ivowen Limited Meet the team Pharmaceutical Regulatory Affairs Services: Human & Veterinary Pg 5 Pg 5 National Procedures
More informationReport from the CMDh meeting held on November 2013
Report from the meeting held on 18-20 November 2013 Pharmacovigilance Outcomes of informal PSUR work-sharing procedures The has adopted the conclusions of PSUR assessment for alprostadil, ciclosporin,
More informationHow to Report Medication Safety Incidents from a GP Practice on the National Reporting and Learning System (NRLS)
pecialist Pharmacy ervice Medicines Use and afety How to Report Medication afety Incidents from a GP Practice on the National Reporting and Learning ystem (NRL) This document provides a quick explanation
More information14 th May Pharmacy Voice. 4 Bloomsbury Square London WC1A 2RP T E
Consultation response Department of Health Rebalancing Medicines Legislation and Pharmacy Regulation: draft orders under section 60 of the Health Act 1999 14 th May 2015 Pharmacy Voice 4 Bloomsbury Square
More informationMEDICATION SAFETY RESEARCH IN THE DIVISION OF SOCIAL PHARMACY, UNIVERSITY OF HELSINKI, FINLAND
MEDICATION SAFETY RESEARCH IN THE DIVISION OF SOCIAL PHARMACY, UNIVERSITY OF HELSINKI, FINLAND Professor Marja Airaksinen 3rd Nordic Social Pharmacy and Health Services Research Conference November 1-2,
More information1. Have you or a member of your family had first-hand experience of an adverse event or experienced harm in a healthcare setting in your country?
Patient Safety p.1 Submission: 82 Name of organisation Mater Dei Hospital, Pathology Labs, MALTA Stakeholder group Member States authority Country MALTA Address Mater Dei Hospital, Tal- Qroqq, MSD 2090
More informationSubmission of new substance and IMP data in the extended EudraVigilance Medicinal Product Dictionary (XEVMPD)
EMA Implementation Working Group with EU Pharmaceutical Industry Associations on the implementation of Article 57(2), second subparagraph of Regulation (EC) No. 726/2004 Submission of new substance and
More informationPSUR and PSUR repository. Legal basis. PSUR/PBRER General comments
PSUR and PSUR repository Mag. Dr. Irmgard Resch Dep. Assessment Pharmacovigilance AGES-Gespräche Vienna, 22.9.2015 www.basg.gv.at Österreichische Agentur für Gesundheit und Ernährungssicherheit GmbH Legal
More informationEvaluating adverse events from patient support and market research programs: proposed best practices and regulatory changes
Evaluating adverse events from patient support and market research programs: proposed best practices and regulatory changes 2 nd Adverse Event Reporting and Safety Strategies Summit December 8-9, 2015
More informationMedication Management Policy and Procedures
POLICY STATEMENT This policy establishes guidelines for ensuring safe and correct management of client medications in accordance with legislative and regulatory requirements and professional practice competency
More informationIII International Conference on Patient Safety -- Patients for Patient Safety. Patient Safety Solutions
III International Conference on Patient Safety -- Patients for Patient Safety Patient Safety Solutions Laura K. Botwinick Co-Director, Joint Commission International Center for Patient Safety Madrid 14
More informationReducing Medication Errors: National Update
Reducing Medication Errors: National Update Ahmed Ameer Medication Safety Officer Ahmed.Ameer@NHS.net Safer Medication Practice & Medical Devices Team 27 th January 2015 Agenda 1. Development of the National
More informationNOTE: The first appearance of terms in bold in the body of this document (except titles) are defined terms please refer to the Definitions section.
TITLE MEDICATION ORDERS SCOPE Provincial APPROVAL AUTHORITY Clinical Operations Executive Committee SPONSOR Provincial Medication Management Committee PARENT DOCUMENT TITLE, TYPE AND NUMBER Not applicable
More informationOverview on diabetes policy frameworks in the European Union and in other European countries
Overview on policy frameworks in the European Union and in other European countries Countries plan Guidelines Belgium Guidelines for good medical practice type 2 The Belgian is limited to newly diagnosed
More informationUPMC POLICY AND PROCEDURE MANUAL
UPMC POLICY AND PROCEDURE MANUAL POLICY: INDEX TITLE: HS-PT1200 Patient Safety SUBJECT: Reportable Patient Events DATE: September 9, 2013 I. POLICY It is the policy of UPMC to encourage and promote a philosophy
More informationEuropean network of paediatric research (EnprEMA)
17 February 2012 EMA/77450/2012 Human Medicines Development and Evaluation Recognition criteria for self assessment The European Medicines Agency is tasked with developing a European paediatric network
More informationVersion Number: 004 Controlled Document Sponsor: Controlled Document Lead:
Chief Investigators and Principal Investigators in Research Policy CONTROLLED DOCUMENT CATEGORY: CLASSIFICATION: PURPOSE Controlled Document Number: Policy Governance To set out the responsibilities of
More informationICH Topic Q4B Annex 6 Uniformity of Dosage Units General Chapter. Step 3
European Medicines Agency December 2008 EMEA/CHMP/ICH/645408/2008 ICH Topic Q4B Annex 6 Uniformity of Dosage Units General Chapter Step 3 ANNEX 6 TO NOTE FOR EVALUATION AND RECOMMENDATION OF PHARMACOPOEIAL
More informationIntroduction. 3. The law gives the GMC four main functions:
Introduction GMC Response Public consultation on the future of electronic commerce and the implementation of the Directive on Electronic commerce (2000/31/EC) 5 November 2010 1. The General Medical Council
More informationUPMC POLICY AND PROCEDURE MANUAL
UPMC POLICY AND PROCEDURE MANUAL POLICY: INDEX TITLE: HS-PT1200 Patient Safety SUBJECT: Reportable Patient Events DATE: December 4, 2015 I. POLICY It is the policy of UPMC to encourage and promote a philosophy
More informationSOP Title: Reporting Adverse Events and New Safety Information
Page 1 of 14 General Control of medication use requires collecting field data about adverse events (AEs) resulting from medication therapy. Regulation 7(B)(2) of Pharmacists Regulations (Medical Products)
More informationBest Practice Guidelines - BPG 9 Managing Medicines in Care Homes
Best Practice Guidelines - BPG 9 Managing Medicines in Care Homes Medicines in Care Homes 1 DOCUMENT STATUS: Approved DATE ISSUED: 10 th November 2015 DATE TO BE REVIEWED: 10 th November 2017 AMENDMENT
More informationMedication Reconciliation with Pharmacy Technicians
Technician Education Day March 29, 2014 Jacksonville, FL Outline with Pharmacy Technicians Roma Merrick RPhT., CPhT. Pharmacy Technician Coordinator St. Vincent s Medical Center Southside Jacksonville,
More informationSetting the Standards- Safeguarding our Patients
Inaugural IMSN Conference 1 st Oct 2010 - Networking for safety Setting the Standards- Safeguarding our Patients June O Shea and Paul Tighe A hospital is no place to be sick Samuel Goldwyn Outline Introduction
More informationEuropean network of paediatric research (EnprEMA)
20 December 2010 EMA/770017/2010 Human Medicines Development and Evaluation Recognition criteria for self assessment The European Medicines Agency is tasked with developing a European paediatric network
More informationIsotretinoin : Review of the Pregnancy Prevention Programme
Safeguarding public health Isotretinoin : Review of the Pregnancy Prevention Programme HCP WG meeting October 2011: Dr Sarah Mee Isotretinoin: UK RMS Introduction In 2003, European referral led to introduction
More informationResponsible medication processes ( pharmaceutical care ) and good pharmaceutical practices for improved patients quality of life and batter healthcare
Responsible medication processes ( pharmaceutical care ) and good pharmaceutical practices for improved patients quality of life and batter healthcare INTRODUCTION This summary provides - an evaluation
More informationCapturing the value of SCOPE to the EU Flagship Event London, 23 November 2016
Capturing the value of SCOPE to the EU Flagship Event London, 23 November 2016 Helen Lee European Commission, Health and Food Safety Directorate General Outline of the presentation Characterisitics of
More informationFostering a Culture of Safety
Fostering a Culture of Safety June 11, 2017 Alabama Society of Health System Pharmacists Presenter: Trey Gwin, RPh, MBA, Medication Safety Coordinator, Infirmary Health Financial Disclosure The speaker
More informationUsing MEDMARX for Reporting and Benchmarking. Anne Skinner, RHIA Katherine Jones, PhD, PT
Using MEDMARX for Reporting and Benchmarking Anne Skinner, RHIA Katherine Jones, PhD, PT Purpose of the Grant: Assist small rural hospitals to Voluntarily report and analyze medication errors Identify
More information1. Have you or a member of your family had first-hand experience of an adverse event or experienced harm in a healthcare setting in your country?
Patient Safety p.1 Submission: 112 Name of organisation Registre des Ostéopathes de France Stakeholder group Other other, please specify Association Country France Address 8 Rue Thalès 33692 MERIGNAC CEDEX
More informationPractising as a midwife in the UK
Practising as a midwife in the UK An overview of midwifery regulation CONTENTS Introduction 3 Section 1: Education 4 Section 2: Joining the register and maintaining registration 6 Section 3: Standards
More informationCompleting E2B(R3) Compliance in Total Safety 7
@ris global Let s Innovate for Life 2016 Completing E2B(R3) Compliance in Total Safety 7 Author: Christian Schmitz-Moormann, Senior Director, Leading Practices Mark Loudon Senior Director, Risk Management
More informationNHS Lanarkshire Policy for the Availability of Unlicensed Medicines
NHS Lanarkshire Policy for the Availability of Unlicensed Medicines Prepared by: NHS Lanarkshire Chief Pharmacist Endorsed by: Area Drug & Therapeutic Committee Previous Version/Date: Primary Policy Date:
More informationEuropean network of paediatric research (Enpr-EMA)
23 January 213 EMA/25452/213, Rev 1 Human Medicines Development and Evaluation Recognition criteria for self assessment The European Medicines Agency is tasked with developing a European paediatric network
More informationPATIENT SAFETY AND QUALITY OF CARE
Special Eurobarometer 411 PATIENT SAFETY AND QUALITY OF CARE SUMMARY Fieldwork: November December 2013 Publication: June 2014 This survey has been requested by the European Commission, Directorate-General
More information5. returning the medication container to proper secured storage; and
111-8-63-.20 Medications. (1) Self-Administration of Medications. Residents who have the cognitive and functional capacities to engage in the self-administration of medications safely and independently
More informationSheffield Teaching Hospitals NHS Foundation Trust
Sheffield Teaching Hospitals NHS Foundation Trust @seamlesssurgery Seamless Surgery Team Sheffield Teaching Hospitals NHS Foundation Trust July 2017 PROUD TO MAKE A DIFFERENCE PROUD TO MAKE A DIFFERENCE
More information